ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
SHENZHEN, China, Jan. 18, 2022. ImmVira ' s breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 19, 2022 Category: Pharmaceuticals Source Type: clinical trials
Rational Vaccines Announces a Clinical Study of the Frequency of Symptomatic Herpes Simplex Type 1 and 2 (HSV-1 and HSV-2) Virus in HIV Patients
WOBURN, Mass. and OXFORD, England, Dec. 14, 2021. Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical trial designed to investigate the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 14, 2021 Category: Pharmaceuticals Source Type: clinical trials
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
Condition: Herpes Genitalis Interventions: Procedure: Blood sampling; Procedure: Anogenital lesion swab collection Sponsor: GlaxoSmithKline Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2021 Category: Research Source Type: clinical trials
